A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women.

T. Ueland, Scott Wilson, A. Islam, B.H. Mullin, A. Devine, J. Bollerslev, Kun Zhu, Richard Prince

    Research output: Contribution to journalArticle

    16 Citations (Scopus)

    Abstract

    Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.
    Original languageEnglish
    Pages (from-to)828-833
    JournalClinical Endocrinology
    Volume71
    Issue number6
    DOIs
    Publication statusPublished - 2009

    Fingerprint

    Osteoprotegerin
    Cohort Effect
    Cohort Studies
    Mortality
    Serum
    Genes
    Odds Ratio
    Atherosclerotic Plaques
    Hypercholesterolemia
    Population
    Cell Biology
    Cardiovascular Diseases
    Biomarkers
    Smoking
    Hypertension
    Calcium
    Bone and Bones

    Cite this

    @article{908cfeac14144c0ca27cc7feeec07a84,
    title = "A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women.",
    abstract = "Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.",
    author = "T. Ueland and Scott Wilson and A. Islam and B.H. Mullin and A. Devine and J. Bollerslev and Kun Zhu and Richard Prince",
    year = "2009",
    doi = "10.1111/j.1365-2265.2009.03605.x",
    language = "English",
    volume = "71",
    pages = "828--833",
    journal = "Clinical Endocrinology",
    issn = "0300-0664",
    publisher = "John Wiley & Sons",
    number = "6",

    }

    A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. / Ueland, T.; Wilson, Scott; Islam, A.; Mullin, B.H.; Devine, A.; Bollerslev, J.; Zhu, Kun; Prince, Richard.

    In: Clinical Endocrinology, Vol. 71, No. 6, 2009, p. 828-833.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women.

    AU - Ueland, T.

    AU - Wilson, Scott

    AU - Islam, A.

    AU - Mullin, B.H.

    AU - Devine, A.

    AU - Bollerslev, J.

    AU - Zhu, Kun

    AU - Prince, Richard

    PY - 2009

    Y1 - 2009

    N2 - Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.

    AB - Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.

    U2 - 10.1111/j.1365-2265.2009.03605.x

    DO - 10.1111/j.1365-2265.2009.03605.x

    M3 - Article

    VL - 71

    SP - 828

    EP - 833

    JO - Clinical Endocrinology

    JF - Clinical Endocrinology

    SN - 0300-0664

    IS - 6

    ER -